ip rule expect
verdict litig novarti sandoz
expect ip enbrel largest franchis
expect signific movement outlin
potenti impact neg rule downsid
posit rule upsid settlement
catalyst verdict expect district
court case novarti gener divis sandoz
valid enbrel ip enbrel one core franchis gener
annual revenu account compani annual product
sale sandoz unit novarti cover mark purcel receiv fda
approv enbrel biosimilar erelzi obtain
preliminari injunct erelzi prior approv sandoz abil
launch depend district court case whose verdict expect
time contend erelzi infring enbrel ip
sandoz contend enbrel ip valid ip estat consist
patent expir district court
rule sandoz favor sandoz could launch erelzi immedi though
launch would risk given would expect appeal
rule believ verdict sandoz favor would signific neg
surpris investor expect consensu current expect biosimilar
enbrel arriv mid-lat
potenti outcom event scenario district court
rule favor sandoz would unabl launch erelzi district
court would rule ip enbrel valid would expect sandoz
appeal decis pursu legal action would also expect
addit compani progress biosimilar enbrel candid
come year parallel believ either situat would present near-
term headwind enbrel scenario district court rule favor
sandoz rule favor sandoz would mean court found
ip enbrel invalid would theoret allow sandoz
abil launch erelzi immedi howev note would like
appeal decis erelzi launch appeal would at-risk
at-risk launch would mean sandoz would potenti respons tripl
damag ip subsequ found valid appeal scenario
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
analyst employ non-u affili regist
finra may associ person member may
subject nasd/nys restrict commun
subject compani public appear trade secur held
settlement reach sandoz settlement could announc
district court rule expect begin
commerci amjevita biosimilar humira start base
agreement like pressur price market
share anti-tnf agent includ enbrel result believ
could pursu settlement allow erelzi market entri around
potenti stock implic outcom scenario
district court rule favor would expect upsid
threat near-term biosimilar competit enbrel remov
would expect impact novn case scenario district court
rule favor sandoz would expect downsid
investor begin lower enbrel tail valu concern mount
abil replac revenu lost biosimilar competit late-
stage pipelin asset novn would expect upsid scenario
sandoz announc settlement would expect upsid
agreement would remov uncertainti biosimilar enbrel
timelin continu patent litig novn would expect minim
posit impact case settlement
base case expect event legal develop
gener difficult predict base case view rule like
favor abl protect base busi
biosimilar navig litig well recent year includ ipr
enbrel last year ptab institut indic
enbrel patent strong defens current base case assum
biosimilar enbrel erelzi and/or molecul enter market
potenti impact rule see david rising note
detail scenario
district court verdict
favor amgen
favor sandoz settlement
entri biosimilar enbrel
enbrel sale
erelzi sale
potenti chang stock
potenti chang novn stock price
note probabl shown illustr forecast precis
seri event account possibl outcom instead illustr
sens rel plausibl select scenario base current industri
note author materi act capac attorney
hold materi intend either legal
opinion legal advic inform provid herein provid possibl
outcom probabl outcom result legal disput
controversi depend varieti factor includ limit
parti histor relationship law pertain case rel litig talent
trial locat juri composit judg composit investor contact
legal advisor issu law relat subject matter
valuat methodolog risk
price target base dcf model use discount rate
termin growth rate onward model base explicit
revenu project current revenu driver neulasta enbrel epogen
aranesp cholesterol lower drug repatha pipelin drive revenu
growth throughout project period pipelin driver includ aimovig
migrain develop biosimilar risk price target includ biosimilar
competit base busi neulasta enbrel failur
novarti equal-weight stock price close chf price target chf
pt deriv dcf product-by-product sale forecast
assum wacc termin growth revers roce cost
capit long term valu driver new drug cosentyx entresto new
expans potenti catalyst alcon spin-off gene therapi
regulatori newsflow price us march data asthma
atop dermat tropifexor nash risk achiev price
target upsid risk pipelin better expect downsid risk payor refus pay
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report matthew
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
www morganstanley com/institutional/research/conflictpolici portugues version polici found www morganstanley com br
import us regulatori disclosur subject compani
januari benefici own class common equiti secur follow compani cover morgan
within last month manag co-manag public offer offer secur abbvi inc
within last month receiv compens invest bank servic abbvi inc
next month expect receiv intend seek compens invest bank servic abbvi inc acceleron
within last month receiv compens product servic invest bank servic abbvi inc
within last month provid provid invest bank servic invest bank client relationship
follow compani abbvi inc alder biopharmaceut inc alnylam
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani abbvi inc amgen inc beigen ltd biogen inc
 co llc make market secur abbvi inc alder biopharmaceut inc
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
use rel rate system use term overweight equal-weight not-rat underweight see definit morgan
stanley assign rate buy hold sell stock cover overweight equal-weight not-rat underweight equival
buy hold sell investor care read definit rate use morgan stanley research addit sinc morgan stanley research
contain complet inform concern analyst view investor care read morgan stanley research entireti infer
content rate alon case rate research use reli upon invest advic investor decis buy sell
stock depend individu circumst investor exist hold consider
januari
stock rate describ appli fundament equiti research appli debt research produc firm
disclosur purpos accord nasd nyse requir includ categori head buy hold sell alongsid
